As a point of reference, Ras (K-, H- and N-RAS combined) mutations are estimated to occur in 9–30% of all cancers. (Cox et al., 2014) Hypotheses regarding the mechanism by which MUC1 overexpression drives cancer progression have focused almost entirely on biochemical interactions of its 72-residue cytosolic domain (Kufe, 2009b), which represents <10% of the overall protein sequence. This evidence concerns the gene MUC1 and cancer.